ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

filgotinib

Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.

Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 22, 201646 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lakefront Biotherapeutics NVits history only230 open or runningphase 3since Sep 22, 2016Aug 10, 2010none ahead
Gilead Sciencesits history only160 open or runningphase 3since Aug 17, 2016Aug 17, 2016none ahead
Alfasigma74 open or runningphase 3since Sep 22, 2016Sep 22, 2016Jun 2027phase 3 · NCT07554495

Also a collaborator on its studies: Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alfasigma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2016First study: phase 3 study in Colitis, UlcerativeFirst studyNCT02914535 · 1,173 enrolled · United States, Argentina, Australia and more
  2. Jan 17, 2017Phase 3 study in Arthritis, RheumatoidNCT03025308 · 2,731 enrolled · United States, Argentina, Australia and more
  3. Mar 14, 2023Phase 3 study in Axial SpondyloarthritisNCT05785611 · 495 enrolled · Belgium, Bulgaria, Czechia and more
  4. Jan 4, 2024Phase 1 study in Arthritis, JuvenileNCT06222034 · 9 enrolled · France, Germany, Poland and more
  5. Mar 4, 2025Phase 3 study in Colitis, UlcerativeNCT06865417 · 80 planned · Belgium, Croatia, France and more
  6. Apr 15, 20262 phase 3 studies in Arthritis, JuvenileNCT07554495, NCT07553182

Ahead

  1. Jun 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07554495
  2. Dec 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07553182
  3. Jun 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT06865417

TargetBeta

“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
delgocitinibruleLEO Pharmaphase 321

Studies

All 7 Alfasigma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553182Arthritis, Juvenile · France, Germany, United Kingdom3RecruitingDec 202780
NCT07554495Arthritis, Juvenile · Belgium, Czechia, France and more3RecruitingJun 202765
NCT06865417Colitis, Ulcerative · Belgium, Croatia, France and more3RecruitingJun 202880
NCT06222034Arthritis, Juvenile · France, Germany, Poland and more1TerminatedJun 17, 20269
NCT05785611Axial Spondyloarthritis · Belgium, Bulgaria, Czechia and more3Active, not recruitingSep 4, 2024495
NCT03025308Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedMay 16, 20252,731
NCT02914535Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedSep 8, 20261,173

How it is read

Names in the registry

  • “Filgotinib”, 32 entries
  • “GLPG0634”, 11 entries
  • “filgotinib”, 3 entries
  • “GLPG0634 50 mg”, 1 entry
  • “GLPG0634 100 mg”, 1 entry

Codes read as this program: GLPG0634.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.